Marked improvement in left ventricular ejection fraction during long-term β-blockade in patients with chronic heart failure: Clinical correlates and prognostic significance

American Heart Journal

Volumn 145, Issue 2, 2003, Pages 292-299

  Metra, Marco ^a,d   Nodari, Savina ^a   Parrinello, Giovanni ^a   Giubbini, Raffaele ^b   Manca, Carlo ^c   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d c/o Spedoli Civili ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL;

ADULT; AGED; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENERAL CONDITION IMPROVEMENT; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT ATRIUM PRESSURE; HEART STROKE VOLUME; HOSPITALIZATION; HUMAN; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

EID: 0037329186     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.105     Document Type: Article

References (29)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
4. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
5. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
6. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation 2001;104:2996-3007.
7. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
8. Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Blsoprolol Study (CIBIS). Circulation 1997;96:2197-205.
9. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
10. Ramahi TM, Longo MD, Cadariu AR, et al. Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy. J Am Coll Cardiol 2001;37:818-24.
11. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. New Engl J Med 2002;346:1357-65.
12. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-96.
13. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91.
14. Metra M, Nodari S, D'Aloia A, et al. A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J 2000;139:511-21.
15. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-16.
16. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001;141:899-907.
17. Cintron G, Johnson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(Suppl 6):VI17-23.
18. Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000;102:546-51.
19. Kawai K, Takaoka H, Hata K, et al. Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 1999;84:671-6.
20. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41.
21. Schleman KA, Lindenfeld JA, Lowes BD, et al. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail 2001;7:4-12.
22. Lindenfeld J, Robertson AD, Lowes BD, et al. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. J Am Coll Cardiol 2001;38:1950-6.
23. Eichhorn EJ, Heesch CM, Risser RC, et al. Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol 1995;25:154-62.
24. DiLenarda A, Gregori D, Sinagra G, et al. Metoprolol in dilated cardiomyopathy: is it possible to identify factors predictive of improvement? J Cardiac Fail 1996;2:87-102.
25. Tang WW, Prikazsky L, Fowler MB. Insulin resistance is associated with the reversal of left ventricular remodeling following carvedilol [abstract]. Circulation 2000;102(Supp II):11-719.
26. Metra M, Nardi M, Giubbini R, et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
27. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103:1428-33.
28. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999;99:786-92.
29. Bristow MR, Zelis R, Nuzzo R, et al. Baseline and three month change in systemic venous norepinephrine as predictors of clinical outcomes in the BEST trial. J Am Coll Cardiol 2001;37(A Suppl A):281.